Japanese Encephalitis Virus, Inactivated

Summary

Japanese Encephalitis Virus, Inactivated (CHEMBL6068364) is an approved vaccine component; indicated across 2 conditions including japanese encephalitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068364
Name	Japanese Encephalitis Virus, Inactivated
Type	Vaccine component
Max phase	4

Also known as: Ixiaro, Japanese encephalitis virus, inactivated, JAPANESE ENCEPHALITIS VIRUS, INACTIVATED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
Japanese encephalitis	4	MONDO:0019209	EFO:0007332

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	2
PHASE4	1
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01398540	PHASE4	COMPLETED	Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine
NCT01296360	PHASE3	COMPLETED	Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
NCT06680128	PHASE1/PHASE2	RECRUITING	A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
NCT05568953	PHASE2	UNKNOWN	An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
NCT01559831	PHASE1	WITHDRAWN	Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
NCT02963909	PHASE1	COMPLETED	A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).